Development and Characterization of Core-Shell Nanoparticles for Anticancer Therapy

Gemcitabine hydrophilic used for the treatment of solid tumours like ovarian, breast, bladder and small-cell lung cancer, pancreatic cancer. In year 1996 FDA approved it for breast cancer treatment but it has a drawback of rapid body clearance by kidney and metabolism by the plasmatic enzyme cytidine-deaminase. The aim of the study is to entrap gemcitabine in Core-Shell nanoparticles which acts an efficient carrier system for increasing drug's efficacy. Gemcitabine loaded with BSA-PLGA core shell Nanoparticle prepared by double emulsion-solvent diffusion evaporation method using a ratio optimized to 1: 4 respectively. The particle size was found to be 237.6 nm and high encapsulation efficiency was achieved with a concentration of 1.5% TPGS as a primary stabilizer and 3% PVA as a secondary stabilizer. The drug loading and encapsulation efficiency of the Nanoparticles was 18 mu g/mg and 35.1% w/w. IC-50 value of the formulation was found to be (10 mu M) in MIA-PaCA 2 cell line.